The antiviral polymerase inhibitor against Mucormycosis in silico perspective

Elfiky A. Abdo, Ibrahim N. Mohamed

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


During the emerging second wave of COVID-19 in India in the previous two months, of rare fungal infections the Mucormycosis, was reported and alarmed the possible epidemic of this fungal disease in COVID-19 patients and recovered persons. The total number of reported Mucormycosis infections is high in India as compared to the global reports. The limited oxygen supplies and the rising of the country's death toll during COVID-19 with the highest record of daily new cases attributed to many reasons including the new variant B.1.617 (delta variant) reported in India and 78 other countries.
Original languageEnglish (US)
Pages (from-to)114-115
Number of pages2
JournalResearch Journal of Biotechnology
Issue number4
StatePublished - Mar 25 2022
Externally publishedYes

Bibliographical note

KAUST Repository Item: Exported on 2022-06-21
Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University are acknowledged.
This publication acknowledges KAUST support, but has no KAUST affiliated authors.


Dive into the research topics of 'The antiviral polymerase inhibitor against Mucormycosis in silico perspective'. Together they form a unique fingerprint.

Cite this